STAT

APRIL 4, 2023

But in a tweet yesterday, the upstart announced that it is selling the Invokana and Invokamet diabetes drugs from Janssen, a unit at Johnson & Johnson. A month’s supply will cost patients $243.90, a significant cut from the lowest price on GoodRx’s website, which is $582.89.

Diabetes 341

Diabetes Drug Pricing 341

STAT

OCTOBER 31, 2024

In 2016, a number of states filed what eventually became the first in a trio of lawsuits against many of the largest generic companies for allegedly coordinating efforts to fix and maintain prices for dozens of medications to treat a variety of ailments. marketplace had functioned competitively.

Diabetes 328

Diabetes Drug Pricing 328

STAT

DECEMBER 19, 2024

Although there is a caveat: This particular metric was based on a subset of just three drugs that were deemed to be fairly priced based on a cost-effectiveness assessment — the Mounjaro type 2 diabetes treatment, and the Wegovy and Qsymia obesity drugs. Continue to STAT+ to read the full story…

Department of Veterans Affairs 287

Department of Veterans Affairs Diabetes Drug Pricing 287

STAT

JUNE 26, 2023

government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence. LONDON — A U.K. Mounjaro, also known as tirzepatide, has U.S.

Diabetes 252

Diabetes Drug Pricing Drug Development 252

STAT

JULY 15, 2024

European health authorities cautioned that patients due to undergo surgery should be warned of a risk of anesthesia complications if they are being treated with diabetes and weight loss drugs from Novo Nordisk and Eli Lilly, Bloomberg News notes. The

Drug Pricing 266

Drug Pricing Biosimilars Diabetes 266

STAT

MARCH 9, 2023

In explaining the move, Sanders noted that Lilly did not reduce prices on all of its insulin products and that the other two big suppliers of the lifesaving diabetes treatment — Sanofi and Novo Nordisk — have not committed to lowering their prices. Continue to STAT+ to read the full story…

Diabetes 246

Diabetes Drug Pricing 246

STAT

AUGUST 16, 2024

  The Centers for Medicare & Medicaid Services released the Maximum Fair Prices (MFPs) for the first 10 drugs subject to negotiation under the Inflation Reduction Act. This is an important moment in prescription drug pricing policy. billion ) in 2026.

Drug Pricing 276

Drug Pricing Diabetes 276

STAT

SEPTEMBER 13, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning, and congratulations on making it through another week. She is very likely the cutest and most relatable animal I’ve ever seen.

Diabetes 287

Diabetes Drug Pricing Drug Development 287

STAT

AUGUST 10, 2023

The company is riding a wave of sky-high demand for its highly effective diabetes and weight-loss drugs, Ozempic and Wegovy, but will extend the limits introduced for Wegovy supplies.  The news came as the drugmaker raised its full-year profit and sales forecasts for a second time.

Drug Pricing 245

Drug Pricing Diabetes 245

STAT

MAY 15, 2024

According to Yale researchers, 14% Americans who need insulin to control their diabetes spend more than 40% of their post-subsistence income (what is available after paying for food and housing) on the drug. Many avoid or ration their treatment because of the high cost.

Diabetes 302

Diabetes Drug Pricing 302

STAT

NOVEMBER 8, 2023

Eli Lilly’s blockbuster drug tirzepatide, sold as Mounjaro for type 2 diabetes, has been cleared to treat obesity, making it the second in a highly effective class of weight loss medications to enter the market.

Diabetes 363

Diabetes Drug Pricing 363

STAT

OCTOBER 8, 2024

Food and Drug Administration for a “reckless and arbitrary” decision to remove a widely prescribed Eli Lilly drug for combating diabetes and obesity from an official shortages list. The FDA noted, though, that a rival drug from Novo Nordisk called Wegovy remains on the shortages list.

Compounding 344

Compounding Compounding Pharmacies Diabetes Drug Pricing 344

STAT

MARCH 29, 2024

Diabetes drugs are too expensive in the U.S., And blockbuster GLP-1 drugs, too, could be a lot less expensive, according to an investigation published this week in JAMA Network Open, with a simple change: robust generic competition. based on an estimate that factors in a 10% to 50% profit margin.

Diabetes 362

Diabetes Drug Pricing 362

STAT

MAY 23, 2023

… Novo Nordisk disclosed that an oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity , STAT writes. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Drug Pricing 246

Drug Pricing Dosage Diabetes 246

STAT

JUNE 14, 2024

Bernie Sanders threatened to subpoena the company over its pricing of the popular diabetes drug Ozempic and the obesity drug Wegovy, the Senate health committee announced Friday. WASHINGTON — Novo Nordisk CEO Lars Fruergaard Jørgensen will testify before the Senate after Sen.

Diabetes 336

Diabetes Drug Pricing 336

STAT

SEPTEMBER 20, 2024

“Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug costs have skyrocketed over the past decade thanks in part to powerful pharmacy benefit managers and their greed,” said Rahul Rao, Deputy Director of the FTC’s Bureau of Competition, in a statement.

Diabetes 363

Diabetes Drug Pricing 363

STAT

DECEMBER 6, 2023

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering.

Diabetes 292

Diabetes Drug Pricing 292

STAT

NOVEMBER 9, 2023

… Eli Lilly’s blockbuster drug tirzepatide, sold as Mounjaro for type 2 diabetes, has been cleared to treat obesity, making it the second in a highly effective class of weight loss medications to enter the market , STAT reports. We hope you find these useful and have a smashing day. The long-awaited U.S.

Diabetes 249

Diabetes Drug Pricing 249

STAT

MAY 9, 2023

Bernie Sanders’ plans for drug pricing interrogations, he told STAT in an interview. WASHINGTON — Wednesday’s Senate hearing on high costs for insulin “is not the end” of Sen. But it will be a show.

Drug Pricing 246

Drug Pricing Diabetes 246

STAT

JUNE 11, 2024

division over the company’s pricing of the popular diabetes drug Ozempic and the obesity drug Wegovy, his office announced Tuesday. WASHINGTON — Senate health committee chair Bernie Sanders has called a vote to subpoena the chief of Novo Nordisk’s U.S. The vote is scheduled for June 18.

Diabetes 318

Diabetes Drug Pricing 318

STAT

OCTOBER 10, 2024

billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition would give the pharmaceutical company an unfair advantage in the burgeoning market for drugs used to treat obesity and diabetes.

Packaging 287

Packaging Diabetes Pharmaceutical Companies Pharmaceutical Companies 287

STAT

MAY 2, 2024

Novo Nordisk defended the prices of its blockbuster diabetes and obesity drugs Ozempic and Wegovy amid a Senate probe into what the company charges.

Diabetes 314

Diabetes Drug Pricing 314

STAT

SEPTEMBER 24, 2024

WASHINGTON — Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo Nordisk’s Ozempic and Wegovy if the company lowers the prices of the treatments.

Diabetes 353

Diabetes Drug Pricing 353

STAT

AUGUST 22, 2023

German drugmaker Boehringer Ingelheim is the latest pharmaceutical company to sue the federal government over a law that would allow Medicare to negotiate certain drug prices, Reuters reports. Continue to STAT+ to read the full story…

Vaccines 246

Vaccines Drug Pricing Diabetes Pharmaceutical Companies 246

PharmaTech

JANUARY 27, 2025

Brian Feth, Jonathan Grinstein, PhD, Beth Willers, and Laks Pernenkil go behind the headlines to discuss major news announcements made during the JP Morgan Healthcare Conference, a wave of new Medicare drug price negotiations, and more.

Drug Pricing 71

Drug Pricing Diabetes 71

STAT

OCTOBER 17, 2024

billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition will harm competition and reduce patient access to popular diabetes and weight loss medicines.

Diabetes 290

Diabetes Packaging Drug Pricing Drug Development 290

STAT

SEPTEMBER 23, 2024

  Medicare doesn’t cover drugs used for weight loss, but Wegovy made the list because it is also approved to reduce major heart complications, according to the paper’s authors. Novo Nordisk makes the drugs, and Medicare is expected to negotiate prices of all three in the next round.

Specialty Pharmacies 328

Specialty Pharmacies Diabetes Drug Pricing 328

BioPharma Dive

JANUARY 17, 2025

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Drug Pricing 113

Drug Pricing Diabetes 113

STAT

JUNE 24, 2024

On top of today’s Alnylam news, we have Congress gearing up to vote on Medicare coverage for multi-cancer screenings and obesity drug coverage. Also, updates on Vertex’s type 1 diabetes cell therapy, and a push for phage therapy. Read the rest…

Diabetes 253

Diabetes Drug Pricing Drug Development 253

Pharmaceutical Commerce

AUGUST 16, 2024

By 2026, the first 10 drugs for individuals with Part D coverage—whose medications are mainly used to treat cancer, diabetes, and heart disease—will see discounts off of list prices ranging from 38-79%.

Drug Pricing 98

Drug Pricing Diabetes 98

pharmaphorum

NOVEMBER 21, 2022

Provention Bio has priced its new type 1 diabetes (T1D) prevention therapy Tzield at $13,850 per vial – equivalent to almost $194,000 for its 14-day course – a higher level than had been predicted by industry observers. It also has an option on global marketing rights to the drug.

Diabetes 116

Diabetes Drug Pricing 116

STAT

JUNE 20, 2024

With the immense demand for GLP-1-based drugs and recurring shortages of the branded treatments, a wide variety of businesses have popped up to offer their own versions of what they claim are GLP-1 drugs. No other company has bid on the contract — to supply 14 million pens for the next three years, at about $2 per pen. The

Diabetes 282

Diabetes Compounding Drug Pricing Drug Development 282

STAT

SEPTEMBER 27, 2023

The New Jersey Democrat has long been an outspoken ally for the industry, sometimes even diverging with his party to shield drugmakers from pricing reforms. In a heated 2019 bill markup, he joined Republicans in voting against amendments to introduce price-hike caps and drug price negotiation in Medicare.

Drug Pricing 259

Drug Pricing Diabetes 259

STAT

MARCH 15, 2024

Final approval will be contingent on the results of an ongoing study designed to show the drug can improve long-term outcomes for patients. Beyond that timeframe, though, Moody’s expects the prescription drug pricing provisions in the Inflation Reduction Act will more significantly constrain industry growth.

Drug Pricing 258

Drug Pricing Biosimilars Diabetes 258

STAT

MARCH 14, 2023

list prices for several insulin products by up to 75%, the latest big drugmaker to take such a step in response to a years-long outcry over the cost of the diabetes treatments. The company plans to cut the list price of its NovoLog insulin by 75%, and the prices for Novolin and Levemir by 65% starting in January 2024.

Diabetes 246

Diabetes Drug Pricing 246

STAT

SEPTEMBER 18, 2024

  A Novo Nordisk executive believes that Ozempic, the blockbuster diabetes shot made by the company, is “very likely” to be one of the next drugs targeted for a price cut in bargaining with the Medicare program, Bloomberg News writes. The Inflation Reduction Act, which allows the U.S.

Hospitals 270

Hospitals Drug Pricing Diabetes 270

STAT

JUNE 12, 2023

Chamber of Commerce sued the federal government over its new Medicare drug-price negotiation program on Friday, arguing that Congress tried to take too much power away from the courts , STAT reports. Merck, which makes a diabetes drug that could be subject to negotiation, filed suit last week. Medicare

Drug Pricing 245

Drug Pricing Diabetes 245